Dosage and administration
For topical use only. Wipe the area surrounding the eye, cleansing the hair, skin and removing debris as needed. Tear stains: apply twice daily for 2 weeks, then as needed.
For topical use only. Wipe the area surrounding the eye, cleansing the hair, skin and removing debris as needed. Tear stains: apply twice daily for 2 weeks, then as needed.
For topical use only. Wipe the area surrounding the eye, cleansing the hair, skin and removing debris as needed. Tear stains: apply twice daily for 2 weeks, then as needed.
ACTIVE INGREDIENT: 0.002% Chlorhexidine Gluconate
INACTIVE INGREDIENTS: Water, Tromethamine Hydrochloride, Tromethamine, Disodium EDTA, Benzalkonium chloride
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Discontinue use if undue irritation occurs. For animal use only. Keep out of reach of children.
Tris-EDTA Chlorhexidine
Patent Pending
For Dogs, Cats & Horses
NDC 86002-105-50
Net Contents: 50 wipes
Manufactured for: DermaZoo™ Pharma,
www.dermazoo.com, info@dermazoo.com
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CHLORHEXIDINE GLUCONATE | ACTIVE INGREDIENT | MOR84MUD8E | 2 | |
| CHLORHEXIDINE | ACTIVE MOIETY | R4KO0DY52L | 2 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 2 | |
| EDETIC ACID | INACTIVE INGREDIENT | 9G34HU7RV0 | 2 | |
| TROMETHAMINE | INACTIVE INGREDIENT | 023C2WHX2V | 2 | |
| TROMETHAMINE HYDROCHLORIDE | INACTIVE INGREDIENT | 383V75M34E | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 86002-105 | 86002-105-00, 86002-105-50 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CHLORHEXIDINE GLUCONATE | MOR84MUD8E | ACTIB |
| WATER | 059QF0KO0R | IACT |
| TROMETHAMINE HYDROCHLORIDE | 383V75M34E | IACT |
| TROMETHAMINE | 023C2WHX2V | IACT |
| EDETIC ACID | 9G34HU7RV0 | IACT |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SHAMPOO / TOPICAL | 0.2 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | OINTMENT / TOPICAL | 0.03 %w/w | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | INJECTION, SOLUTION / SUBCUTANEOUS | 2 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRAMUSCULAR | 437 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | LOTION / TOPICAL | 0.1 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / OPHTHALMIC | 2 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRA-ARTERIAL | 300 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / OPHTHALMIC | 1 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRA-ARTERIAL | 562 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / TOPICAL | 0.01 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SUSPENSION / INTRATYMPANIC | 2 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SUSPENSION / ENDOTRACHEAL | 2.42 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / INTRAVENOUS | 0.12 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION/ DROPS / OPHTHALMIC | 0.8 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / AURICULAR (OTIC) | 0.01 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / TOPICAL | 8.4 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRAMUSCULAR | 1 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / OPHTHALMIC | 0.02 %w/v | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | SUPPOSITORY / RECTAL | 7 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / TOPICAL | 0.02 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION, GEL FORMING / DROPS / OPHTHALMIC | 1 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / INTRAVASCULAR | 0.12 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / NASAL | 40.46 mg/100ml | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | GEL / TRANSDERMAL | 10 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / AURICULAR (OTIC) | 0 %w/v | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | TABLET / ORAL | 4 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.24 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | TABLET / ORAL | 30 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | GEL / OPHTHALMIC | 0.01 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAVENOUS | 300 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 6.06 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / RESPIRATORY (INHALATION) | 0.02 %w/w | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | GEL / TOPICAL | 0.1 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / OPHTHALMIC | 1 mg | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | INJECTION, SOLUTION / SUBMUCOSAL | 0.03 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / ORAL | 1.21 mg/1ml | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.8 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / RECTAL | 0.12 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRA-ARTICULAR | 1 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / RESPIRATORY (INHALATION) | 0.01 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | SUSPENSION / TOPICAL | 0.06 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | CLOTH / TOPICAL | NA | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | CAPSULE / ORAL | 30 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | LIQUID / NASAL | 0.2 mg/1ml | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | INJECTION, SOLUTION / INTRAMUSCULAR | 2 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRALESIONAL | 1 mg | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | SUSPENSION / AURICULAR (OTIC) | NA | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / TOPICAL | NA | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.02 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | GEL / TOPICAL | 56 mg | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | SHAMPOO / TOPICAL | 0.2 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAMUSCULAR | 1.21 %w/v | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | SOLUTION / TOPICAL | 0.5 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRAVENOUS | 1134 mg | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | TABLET, FILM COATED / ORAL | 0.2 mg | ||
| EDETIC ACID | EDETIC ACID | 9G34HU7RV0 | INJECTION, SOLUTION / INTRAVENOUS | 2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Adverse event summaries are temporarily unavailable. Other product information remains available.